[go: up one dir, main page]

RU2016151730A - Antibodies for laboratory diagnosis of interleukin-11 concentration - Google Patents

Antibodies for laboratory diagnosis of interleukin-11 concentration Download PDF

Info

Publication number
RU2016151730A
RU2016151730A RU2016151730A RU2016151730A RU2016151730A RU 2016151730 A RU2016151730 A RU 2016151730A RU 2016151730 A RU2016151730 A RU 2016151730A RU 2016151730 A RU2016151730 A RU 2016151730A RU 2016151730 A RU2016151730 A RU 2016151730A
Authority
RU
Russia
Prior art keywords
seq
sequences
amino acid
acid sequence
sequence selected
Prior art date
Application number
RU2016151730A
Other languages
Russian (ru)
Other versions
RU2016151730A3 (en
Inventor
Тажиб Ахмедханович Мирзабеков
Роман Вячеславович Михайлов
Андрей Романович Яковенко
Сергей Евгеньевич Пермяков
Людмила Викторовна Ермолина
Андрей Сергеевич Соколов
Екатерина Владимировна Павлова
Евгений Анатольевич Пермяков
Original Assignee
Федеральное государственное бюджетное учреждение науки Институт биологического приборостроения с опытным производством Российской Академии наук (ИБП РАН)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Федеральное государственное бюджетное учреждение науки Институт биологического приборостроения с опытным производством Российской Академии наук (ИБП РАН) filed Critical Федеральное государственное бюджетное учреждение науки Институт биологического приборостроения с опытным производством Российской Академии наук (ИБП РАН)
Priority to RU2016151730A priority Critical patent/RU2016151730A/en
Publication of RU2016151730A publication Critical patent/RU2016151730A/en
Publication of RU2016151730A3 publication Critical patent/RU2016151730A3/ru

Links

Landscapes

  • Peptides Or Proteins (AREA)

Claims (14)

1. Антитела против ИЛ-11 человека, или их производные, или антигенсвязывающие фрагменты антител, содержащие не менее одного из указанных ниже гипервариабельных участков тяжелой (HCDR) или легкой (LCDR) цепи:1. Antibodies against human IL-11, or their derivatives, or antigen-binding fragments of antibodies containing at least one of the following hypervariable regions of the heavy (HCDR) or light (LCDR) chain: a) HCDR1 участок содержит аминокислотную последовательность, выбранную из следующей группы последовательностей:a) the HCDR1 region contains an amino acid sequence selected from the following group of sequences: Seq ID NO 1: FTFTGYWMNWVRSeq ID NO 1: FTFTGYWMNWVR Seq ID NO 2: FTFTDYWMNWVRSeq ID NO 2: FTFTDYWMNWVR b) HCDR2 участок содержит аминокислотную последовательность, выбранную из следующей группы последовательностей:b) the HCDR2 region contains an amino acid sequence selected from the following group of sequences: Seq ID NO 3: VSSISSYGGGTYYADSSeq ID NO 3: VSSISSYGGGTYYADS Seq ID NO 4: VSTIASSNSYTDYADSSeq ID NO 4: VSTIASSNSYTDYADS c) HCDR3 участок содержит аминокислотную последовательность, выбранную из следующей группы последовательностей:c) The HCDR3 region contains an amino acid sequence selected from the following group of sequences: Seq ID NO 5: CARESLHQLFDYWGQSeq ID NO 5: CARESLHQLFDYWGQ Seq ID NO 6: CARESWSEGWWPSGFDYWGQSeq ID NO 6: CARESWSEGWWPSGFDYWGQ d) LCDR3 участок содержит аминокислотную последовательность, выбранную из следующей группы последовательностей:d) LCDR3 region contains an amino acid sequence selected from the following group of sequences: Seq ID NO 7: CQQSYSYAPITFGQSeq ID NO 7: CQQSYSYAPITFGQ Seq ID NO 8: CQQYETSPITFGQSeq ID NO 8: CQQYETSPITFGQ 2. Способ определения концентрации ИЛ-11 человека и модельных животных, например, яванской макаки, в биологических жидкостях при помощи методов иммуноанализа, заключающийся в том, что 1) образец исследуемой жидкости приводят в контакт с антителом по п. 1 и 2) оценивают концентрацию иммунных комплексов в реакционной смеси.2. A method for determining the concentration of IL-11 in humans and model animals, for example, cynomolgus monkey, in biological fluids using immunoassay methods, which consists in the fact that 1) a sample of the test fluid is brought into contact with the antibody according to p. 1 and 2) evaluate the concentration immune complexes in the reaction mixture.
RU2016151730A 2016-12-28 2016-12-28 Antibodies for laboratory diagnosis of interleukin-11 concentration RU2016151730A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
RU2016151730A RU2016151730A (en) 2016-12-28 2016-12-28 Antibodies for laboratory diagnosis of interleukin-11 concentration

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
RU2016151730A RU2016151730A (en) 2016-12-28 2016-12-28 Antibodies for laboratory diagnosis of interleukin-11 concentration

Related Child Applications (1)

Application Number Title Priority Date Filing Date
RU2020111785A Previously-Filed-Application RU2763178C2 (en) 2020-03-23 2020-03-23 Antibodies for laboratory diagnostics of the concentration of interleukin-11

Publications (2)

Publication Number Publication Date
RU2016151730A true RU2016151730A (en) 2018-06-29
RU2016151730A3 RU2016151730A3 (en) 2019-02-15

Family

ID=62814078

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2016151730A RU2016151730A (en) 2016-12-28 2016-12-28 Antibodies for laboratory diagnosis of interleukin-11 concentration

Country Status (1)

Country Link
RU (1) RU2016151730A (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019238882A1 (en) * 2018-06-13 2019-12-19 Singapore Health Services Pte. Ltd. Il-11 antibodies
US10822405B2 (en) 2015-12-16 2020-11-03 Singapore Health Services Pte Ltd. Treatment of fibrosis with IL-11 receptor alpha antibody
US11078269B2 (en) 2016-12-16 2021-08-03 Singapore Health Services Pte Ltd IL-11Rα antibodies
US11078268B2 (en) 2016-12-16 2021-08-03 Singapore Health Services Pte Ltd IL-11 antibodies
US11319368B2 (en) 2019-01-21 2022-05-03 Singapore Health Services Pte Ltd. Treatment of hepatotoxicity with IL-11 antibody

Cited By (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10894827B2 (en) 2015-12-16 2021-01-19 Singapore Health Services Pte Ltd Treatment of fibrosis with interleukin-11 receptor alpha antibody
US10894825B2 (en) 2015-12-16 2021-01-19 Singapore Health Services Pte Ltd Treatment of fibrosis with interleukin-11 antibody
US10865241B2 (en) 2015-12-16 2020-12-15 Singapore Health Services Pte Ltd. Treatment of fibrosis with interleukin-11 antibody
US10865239B2 (en) 2015-12-16 2020-12-15 Singapore Health Services Pte Ltd. Treatment of fibrosis with interleukin-11 antibody
US10865240B2 (en) 2015-12-16 2020-12-15 Singapore Health Services Pte Ltd. Treatment of fibrosis with interleukin-11 antibody
US10870697B2 (en) 2015-12-16 2020-12-22 Singapore Health Services Pte Ltd. Treatment of fibrosis with interleukin-11 antibody
US10870696B2 (en) 2015-12-16 2020-12-22 Singapore Health Services Pte Ltd. Treatment of fibrosis with interleukin-11 antibody
US10889642B2 (en) 2015-12-16 2021-01-12 Singapore Health Services Pte Ltd Treatment of fibrosis with interleukin-11 receptor alpha antibody
US10822405B2 (en) 2015-12-16 2020-11-03 Singapore Health Services Pte Ltd. Treatment of fibrosis with IL-11 receptor alpha antibody
US11939374B2 (en) 2015-12-16 2024-03-26 Singapore Health Services Pte Ltd. Treatment of fibrosis
US10894826B2 (en) 2015-12-16 2021-01-19 Singapore Health Services Pte Ltd Treatment of fibrosis with interleukin-11 receptor alpha antibody
US10899832B2 (en) 2015-12-16 2021-01-26 Singapore Health Services Pte Ltd Treatment of fibrosis with interleukin-11 receptor alpha antibody
US10927169B2 (en) 2015-12-16 2021-02-23 Singapore Health Services Pte Ltd Treatment of fibrosis with Interleukin-11 receptor alpha antibody
US11078269B2 (en) 2016-12-16 2021-08-03 Singapore Health Services Pte Ltd IL-11Rα antibodies
US11078268B2 (en) 2016-12-16 2021-08-03 Singapore Health Services Pte Ltd IL-11 antibodies
US11084874B2 (en) 2018-06-13 2021-08-10 Singapore Health Services Pte Ltd. IL-11 antibodies
WO2019238882A1 (en) * 2018-06-13 2019-12-19 Singapore Health Services Pte. Ltd. Il-11 antibodies
US11319368B2 (en) 2019-01-21 2022-05-03 Singapore Health Services Pte Ltd. Treatment of hepatotoxicity with IL-11 antibody

Also Published As

Publication number Publication date
RU2016151730A3 (en) 2019-02-15

Similar Documents

Publication Publication Date Title
RU2016151730A (en) Antibodies for laboratory diagnosis of interleukin-11 concentration
JP2020536488A5 (en)
NZ716369A (en) Anti-ox40 antibodies and methods of using the same
RU2015103228A (en) ANTIBODIES AGAINST TAU
RU2014146707A (en) ANTIBODIES AGAINST TOFACITINIBE AND THEIR APPLICATION FOR MEDICINAL MONITORING
JP2021500916A5 (en)
AR125212A1 (en) PROTEINS INCLUDING CD3 ANTIGEN-BINDING DOMAINS AND THEIR USES
RU2012134369A (en) BIOMARKERS OF IMMUNOMODULATING EFFECTS IN PEOPLE EXPOSED TO ANTIMETAL TREATMENT AGAINST CD200
KR20130135028A (en) Rapid isolation of monoclonal antibodies from animals
RU2010133547A (en) ANTI-CLDN ANTIBODIES
PE20230389A1 (en) PROTEINS THAT COMPRISE BINDING DOMAINS TO THE CD3 ANTIGEN AND USES OF THESE
KR20150041801A (en) Complex-specific antibodies and antibody fragments and its use
RU2011121818A (en) METHOD FOR IMMUNOLOGICAL ANALYSIS OF HUMAN PROTEIN CXCL1
EP2295465A3 (en) Human monoclonal antibodies to influenza M2 protein and methods of making and using same
HRP20171067T1 (en) Therapeutic use of specific ligand in msrv associated diseases
RU2015115399A (en) Antigens Associated with Inflammatory Bowel Disease
HRP20192038T1 (en) Anti-epidermal growth factor receptor (egfr) antibodies
US10247739B2 (en) Method for immunological measurement using a hapten and antibody binding to the hapten as reference antibody and device for immunological measurement using the reference antibody
RU2016129166A (en) ANTIBODIES SPECIFIC TO ALPHA ENOLASE AND METHODS OF APPLICATION IN ANTITUMOR THERAPY
RU2017132168A (en) ANTIBODIES AIMED AT O-ANTIGEN BASED ON GALACTHAN FROM K.PNEUMONIAE
AR121857A1 (en) ANTI-OX40 ANTIBODY AND USES OF THE SAME
JP2020189843A5 (en)
AR117548A1 (en) MONOCLONAL ANTIBODIES SPECIFIC TO THE HUMAN PARAINFLUENZA VIRUS (PIV) CHIMERIC PROTEIN L, NUCLEOTHICAL SEQUENCES; PIV INFECTION DIAGNOSTIC KIT AND METHOD
CN104062430B (en) A kind of kit for detecting influenza virus in sample and detection method thereof and application
JP2019513346A5 (en)

Legal Events

Date Code Title Description
HZ9A Changing address for correspondence with an applicant
FA91 Application withdrawn (on applicant's request)

Effective date: 20200323